BRPI0811947A2 - Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica - Google Patents
Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólicaInfo
- Publication number
- BRPI0811947A2 BRPI0811947A2 BRPI0811947-3A2A BRPI0811947A BRPI0811947A2 BR PI0811947 A2 BRPI0811947 A2 BR PI0811947A2 BR PI0811947 A BRPI0811947 A BR PI0811947A BR PI0811947 A2 BRPI0811947 A2 BR PI0811947A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- dyslipidemia
- diabetes
- preparation
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93130307P | 2007-05-22 | 2007-05-22 | |
US93132707P | 2007-05-22 | 2007-05-22 | |
US93127307P | 2007-05-22 | 2007-05-22 | |
US93136907P | 2007-05-22 | 2007-05-22 | |
PCT/EP2008/055843 WO2008141976A1 (en) | 2007-05-22 | 2008-05-13 | Diacylglycerol acyltransferase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0811947A2 true BRPI0811947A2 (pt) | 2014-11-11 |
Family
ID=39619031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0811947-3A2A BRPI0811947A2 (pt) | 2007-05-22 | 2008-05-13 | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2155687A1 (es) |
CN (1) | CN101835757B (es) |
AU (1) | AU2008253118B2 (es) |
BR (1) | BRPI0811947A2 (es) |
CA (1) | CA2686951C (es) |
HK (1) | HK1148519A1 (es) |
MX (1) | MX2009012285A (es) |
WO (1) | WO2008141976A1 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ555683A (en) | 2004-12-14 | 2010-09-30 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
AR058562A1 (es) | 2005-12-22 | 2008-02-13 | Astrazeneca Ab | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 |
PL2402319T3 (pl) | 2006-03-31 | 2018-02-28 | Novartis Ag | Inhibitory DGAT |
ES2356097T3 (es) | 2006-05-30 | 2011-04-04 | Astrazeneca Ab | Ácidos 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-ciclohexancarboxílico sustituidos como inhibidores de la acetil coenzima a diacilglicerol aciltransferasa. |
US8115011B2 (en) | 2007-05-22 | 2012-02-14 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US8058299B2 (en) | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US8153644B2 (en) | 2007-05-22 | 2012-04-10 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
JO2972B1 (en) * | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
CA2687912C (en) | 2007-06-08 | 2015-11-03 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
US8633197B2 (en) | 2007-06-08 | 2014-01-21 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
UY31863A (es) | 2008-06-05 | 2010-01-05 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
US8211884B2 (en) | 2008-08-06 | 2012-07-03 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
JP2012509274A (ja) | 2008-11-19 | 2012-04-19 | シェーリング コーポレイション | ジアシルグリセロールアシルトランスフェラーゼの阻害薬 |
WO2010065310A1 (en) * | 2008-12-03 | 2010-06-10 | Via Pharmaceuticals, Inc | Inhibitors of diacylglycerol acyltransferase |
WO2010077861A1 (en) * | 2008-12-17 | 2010-07-08 | Via Pharmaceuticals, Inc | Inhibitors of diacylglycerol aclytransferase |
WO2010101246A1 (ja) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Npy y5受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
WO2011078102A1 (ja) * | 2009-12-22 | 2011-06-30 | 第一三共株式会社 | 新規フェノキシピリミジン誘導体 |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US9150555B2 (en) | 2010-10-14 | 2015-10-06 | Mitsubishi Tanabe Pharma Corporation | Amide derivative and use thereof |
TW201236685A (en) * | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
US9452995B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
CN102924444B (zh) * | 2011-08-11 | 2015-07-08 | 上海吉铠医药科技有限公司 | Pim激酶抑制剂及其制备方法与在制药中的应用 |
US9458151B2 (en) * | 2011-08-11 | 2016-10-04 | Jikai Biosciences, Inc. | Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
US9453003B2 (en) * | 2011-08-11 | 2016-09-27 | Jikai Biosciences, Inc. | Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof |
CA2868164A1 (en) | 2012-04-13 | 2013-10-17 | Mitsubishi Tanabe Pharma Corporation | Amidopyridine derivative and use thereof |
CN104672165B (zh) * | 2015-02-10 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一类含环丙基脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途 |
CN104672166A (zh) * | 2015-02-10 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 一种含脒结构的腈基苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途 |
CN104610187B (zh) * | 2015-02-10 | 2016-04-06 | 佛山市赛维斯医药科技有限公司 | 一类含脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途 |
CN104557765A (zh) * | 2015-02-10 | 2015-04-29 | 佛山市赛维斯医药科技有限公司 | 一类含脒结构的卤代苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途 |
CN104610189A (zh) * | 2015-02-10 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含环丙基脒结构sglt2/sglt1双靶点抑制剂及用途 |
CN104710382A (zh) * | 2015-02-10 | 2015-06-17 | 佛山市赛维斯医药科技有限公司 | 一类含叔丁基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途 |
CN104592149A (zh) * | 2015-02-10 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 一类含叔丁基脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途 |
CN104672164A (zh) * | 2015-02-10 | 2015-06-03 | 佛山市赛维斯医药科技有限公司 | 一类含苯基脒结构的sglt2/sglt1双靶点抑制剂、其制备方法及用途 |
CN104592151A (zh) * | 2015-02-10 | 2015-05-06 | 佛山市赛维斯医药科技有限公司 | 一类含叔丁基脒结构sglt2/sglt1双靶点抑制剂及用途 |
BR112018015389B1 (pt) | 2016-03-17 | 2023-12-19 | F. Hoffmann-La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso |
CA3072362A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
BR112020021921A2 (pt) | 2018-05-17 | 2021-01-26 | Forma Therapeutics, Inc. | compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina |
LT3860989T (lt) | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE347890T1 (de) * | 2001-08-31 | 2007-01-15 | Sanofi Aventis Deutschland | Diarylcycloalkylderivate, verfahren zu ihrer herstellung und ihre verwendung als ppar- aktivatoren |
WO2004022551A1 (ja) * | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | フランまたはチオフェン誘導体およびその医薬用途 |
WO2006134317A1 (en) * | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
EP1963313B1 (en) * | 2005-11-28 | 2012-11-14 | Madrigal Pharmaceuticals, Inc. | Inhibitors of diacylglycerol acyltransferase (dgat) |
-
2008
- 2008-05-13 WO PCT/EP2008/055843 patent/WO2008141976A1/en active Application Filing
- 2008-05-13 CN CN200880025656.1A patent/CN101835757B/zh not_active Expired - Fee Related
- 2008-05-13 EP EP08759547A patent/EP2155687A1/en not_active Withdrawn
- 2008-05-13 MX MX2009012285A patent/MX2009012285A/es active IP Right Grant
- 2008-05-13 BR BRPI0811947-3A2A patent/BRPI0811947A2/pt not_active IP Right Cessation
- 2008-05-13 CA CA2686951A patent/CA2686951C/en not_active Expired - Fee Related
- 2008-05-13 AU AU2008253118A patent/AU2008253118B2/en not_active Ceased
-
2011
- 2011-03-15 HK HK11102583.6A patent/HK1148519A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101835757B (zh) | 2014-03-05 |
MX2009012285A (es) | 2009-12-15 |
AU2008253118A1 (en) | 2008-11-27 |
CA2686951A1 (en) | 2008-11-27 |
WO2008141976A1 (en) | 2008-11-27 |
AU2008253118B2 (en) | 2013-11-21 |
CN101835757A (zh) | 2010-09-15 |
EP2155687A1 (en) | 2010-02-24 |
CA2686951C (en) | 2016-03-22 |
HK1148519A1 (en) | 2011-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0811947A2 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI0814825A2 (pt) | Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii | |
BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BRPI0715531A2 (pt) | Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto | |
BRPI0907977A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0717657A2 (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii | |
BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
BRPI0816881A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto. | |
BRPI0914927A2 (pt) | composto, composição farmacêutica, métodos para inibir a função de fak e de tratamento de um câncer, uso de um composto, e, processo para preparar um composto | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BR122020011920A2 (pt) | composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto | |
BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
BRPI0922475A2 (pt) | composto, composição farmacêutica , método para tratar câncer, e, uso de um composto. | |
BRPI0810246A2 (pt) | Inibidores da dpp-iv incluindo o grupo beta-amino, método de preparação do mesmo e composição farmacêutica contendo o mesmo para prevenção e tratamento da diabetes ou obesidade. | |
BRPI0924669A2 (pt) | composto, uso de um composto, método para tratar a diabete melito e/ou obesidade, e, composição farmacêutica | |
BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
BRPI0915084A2 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
BR112012015248A2 (pt) | composto composição farmacêutica,método para inibir ativi dades de ck1, método para inibir atividade de ck2 e uso de um composto ou uma composição farmacêutica | |
BRPI0815493A2 (pt) | Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto. | |
BRPI0908883A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |